These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. Kovar H Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919 [TBL] [Abstract][Full Text] [Related]
3. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270 [TBL] [Abstract][Full Text] [Related]
4. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472 [TBL] [Abstract][Full Text] [Related]
5. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725 [TBL] [Abstract][Full Text] [Related]
7. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492 [TBL] [Abstract][Full Text] [Related]
8. The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma. Boone MA; Taslim C; Crow JC; Selich-Anderson J; Byrum AK; Showpnil IA; Sunkel BD; Wang M; Stanton BZ; Theisen ER; Lessnick SL Oncogene; 2021 Jul; 40(29):4759-4769. PubMed ID: 34145397 [TBL] [Abstract][Full Text] [Related]
9. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma. Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018 [TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma. Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma. Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407 [TBL] [Abstract][Full Text] [Related]
14. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy. Romo-Morales A; Aladowicz E; Blagg J; Gatz SA; Shipley JM Pediatr Blood Cancer; 2019 Sep; 66(9):e27888. PubMed ID: 31207107 [TBL] [Abstract][Full Text] [Related]
15. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue. Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302 [TBL] [Abstract][Full Text] [Related]
16. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381 [TBL] [Abstract][Full Text] [Related]
17. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Osgood CL; Maloney N; Kidd CG; Kitchen-Goosen S; Segars L; Gebregiorgis M; Woldemichael GM; He M; Sankar S; Lessnick SL; Kang M; Smith M; Turner L; Madaj ZB; Winn ME; Núñez LE; González-Sabín J; Helman LJ; Morís F; Grohar PJ Clin Cancer Res; 2016 Aug; 22(16):4105-18. PubMed ID: 26979396 [TBL] [Abstract][Full Text] [Related]
18. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells. Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567 [TBL] [Abstract][Full Text] [Related]
19. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455 [TBL] [Abstract][Full Text] [Related]
20. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]